Whalesbook
Pharma Plunge vs. Fintech Turnaround in Mixed Q4 Earnings
Indian corporate earnings for the fourth quarter of fiscal year 2026 presented a stark contrast. While pharmaceutical giant Dr. Reddy's Laboratories grappled with an 86% year-on-year profit collapse, fintech player MobiKwik successfully returned to profitability. This divergence highlighted a challenging earnings season where sector issues and one-time events heavily impacted profits, even as other sectors showed strength.
Key Q4 Performance: Pharma Losses and Fintech Gains
Dr. Reddy's Laboratories reported a dramatic 86.2% decline in its net profit to ₹220.1 crore for Q4 FY26. This sharp fall was primarily attributed to significant one-time charges, including a ₹453 crore shelf stock adjustment related to lenalidomide, impairment charges of ₹228 crore for CAR-T assets, and ₹114 crore in VAT liability provisions. Revenue also contracted by 11.64% year-on-year to ₹7,516.2 crore. Excluding these exceptional items, adjusted revenues showed a less severe decline, suggesting underlying operational strength, but the reported figures painted a grim picture that led to investor concerns and a subsequent stock price reaction.
Meanwhile, MobiKwik Systems achieved a net profit of ₹4.38 crore in Q4 FY26, a significant turnaround from the ₹56 crore loss reported in the same quarter last year. This return to the black was driven by stringent cost discipline and improved business efficiency, with revenue growing 7.8% year-on-year to ₹289 crore. Despite this positive profit development, the stock experienced a 3.5% decline, reflecting market caution over largely flat sequential profitability and ongoing investments in new business segments.
Broader Earnings Picture: Varied Sector Results
Elsewhere in Q4 FY26 results, a wide range of corporate performance was on display. Industrial and manufacturing companies largely posted strong results. MTAR Technologies reported strong growth, with revenue soaring 67.2% year-on-year to ₹306.1 crore and net profit leaping 222.3% to ₹44.3 crore. Similarly, Inox India reported a 15% rise in net profit to ₹75.2 crore on a 25% revenue climb, driven by its cryogenic equipment and industrial gas solutions businesses.
Berger Paints India reported strong profit growth of 27.5% to ₹335 crore, supported by 11.8% volume growth, an improved product mix, and softening raw material costs, leading to expanded gross margins. Tata Power also posted an 8.3% rise in consolidated net profit to ₹1,415.52 crore, despite a 13% dip in revenue, with its renewable energy and transmission businesses being key contributors.
However, not all segments showed strength. Dixon Technologies, a major player in electronics manufacturing services, saw its Q4 FY26 net profit fall 36% to ₹256 crore, as revenue grew only 2%. This decline was attributed to margin compression, driven by rising component costs and the conclusion of the production-linked incentive (PLI) scheme, which provided crucial margin support previously. Nazara Technologies, in the gaming sector, saw profits jump threefold to ₹55.7 crore, even as revenue declined 24%. This profit surge was significantly boosted by substantial 'other income' and reduced operating expenses.
Texmaco Rail & Engineering showed resilience with a 62% profit rise to ₹58 crore on marginally higher revenue, further bolstered by a significant $430 million (approximately ₹4,045 crore) export order and a strategic ₹200 crore investment in its defence subsidiary.
Investor Concerns on Dr. Reddy's, Dixon, MobiKwik
Concerns are being raised about the sustainability of Dr. Reddy's Laboratories' profitability following its Q4 performance. The large drop in net profit, margin compression to 5.09% from 23.49% a year ago, and double-digit revenue decline point to significant operational challenges. Although the company cited one-time items, the scale of these charges and their earnings impact suggest deeper issues affecting its core business, especially with the lenalidomide patent expiry and price drops in key markets. Reliance on 'other income' or asset write-downs to mask operational performance can be a warning sign.
Dixon Technologies faces pressure from the end of the crucial mobile production PLI scheme, which previously supported its margins. The company's reported margin drop and warnings of near-term pressure before backward integration benefits could materialize suggest a cautious outlook.
For MobiKwik, while returning to profit is positive, flat sequential growth combined with its stock decline indicates market participants seek more robust revenue growth and sustained profitability beyond cost cuts.
Looking Ahead
As the Q4 FY26 earnings season concludes, investors are closely examining companies' earnings quality, revenue growth, and margin sustainability. The varied results highlight how economic factors, sector policies (like PLI expiry), and company-specific events can significantly impact performance. Companies showing consistent revenue growth with disciplined cost management and margin expansion, like Berger Paints and MTAR Technologies, are likely to gain investor confidence. Conversely, those relying on one-time gains or facing structural challenges, like Dr. Reddy's and Dixon Technologies, will face increased scrutiny over their future earnings visibility and competitive standing.